Table 2 The cost of medication therapy scenario and household OOP payments per treatment schedule
From: Catastrophic pharmaceutical expenditure in patients with type 2 diabetes in Iran
Medication therapy regimens | Treatment schedules | Treatment cost (30 days) * | Household OOP* | Share of OOP of treatment cost | |
|---|---|---|---|---|---|
Mono therapy | Metformin, | 36,000 | 10,800 | 30% | |
Glibenclamide | 15,000 | 4,500 | 30% | ||
Gliclazide | 24.000 | 7,200 | 30% | ||
Dual therapy | Metformin + Acarbose | 159,000 | 47,700 | 30% | |
Metformin + Repaglinide | 243,000 | 72,900 | 30% | ||
Metformin + Glibenclamide | 123,000 | 36,900 | 30% | ||
Metformin + Gliclazide | 132,000 | 39,600 | 30% | ||
Metformin + Pioglitazone | 171,000 | 51,300 | 30% | ||
Triple therapy | A) Oral therapy | Metformin + Pioglitazone + Glibenclamde | 186,000 | 55,800 | 30% |
Metformin + Pioglitazone + Gliclazide | 195,000 | 58,500 | 30% | ||
Metformin + Pioglitazone + Acarbose | 222,000 | 66,600 | 30% | ||
B) Oral therapy + Insulins | Metformin + Insulin isophane | 122,400 | 116,280 | 95% | |
Metformin + Insulin glargine | 306,900 | 291,555 | 95% | ||
Metformin + Insulin detemir | 3,303,000 | 990,900 | 30% | ||